Publications by authors named "Pablo J Palomo"
Background: Higher drug levels and combination therapy with low-dose oral methotrexate (LD-MTX) may reduce anti-tumor necrosis factor (TNF) treatment failure in pediatric Crohn's disease. We sought to (1) evaluate whether combination therapy with LD-MTX was associated with higher anti-TNF levels, (2) evaluate associations between anti-TNF levels and subsequent treatment failure, and (3) explore the effect of combination therapy on maintenance of remission among patients with therapeutic drug levels (>5 µg/mL for infliximab and >7.5 µg/mL for adalimumab).
View Article and Find Full Text PDFArticle Synopsis
- A multicenter trial was conducted to compare the effectiveness of tumor necrosis factor inhibitors combined with oral methotrexate versus those without methotrexate in pediatric patients with Crohn's disease.
- The study involved 297 participants, revealing that combination therapy did not significantly improve treatment outcomes for infliximab initiators, but did show a longer time to treatment failure for adalimumab initiators.
- Although combination therapy led to more adverse events overall, it resulted in fewer serious adverse events, with no significant differences reported in patient-reported outcomes of pain and fatigue.